Noncardiac chest pain

Journal of Clinical Gastroenterology

Volumn 42, Issue 5, 2008, Pages 636-646

  Fass, Ronnie ^a,b   Navarro Rodriguez, Tomás ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Gastroesophageal reflux disease; Lower esophageal sphincter; Noncardiac chest pain; Nonspecific esophageal motility disorder

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CIMETROPIUM; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; DILTIAZEM; ESOMEPRAZOLE; GLYCERYL TRINITRATE; HYDRALAZINE; IMIPRAMINE; LANSOPRAZOLE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRIC ACID DERIVATIVE; OCTREOTIDE; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SILDENAFIL; TEGASEROD; THEOPHYLLINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANTIREFLUX OPERATION; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONFERENCE PAPER; DRUG ACTIVATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DYSPHAGIA; ELECTROSTIMULATION; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS FUNCTION DISORDER; EVENING DOSAGE; FOOT EDEMA; FUNCTIONAL DISEASE; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERALGESIA; HYPERSENSITIVITY; HYPNOSIS; HYPOTENSION; LIFESTYLE MODIFICATION; MAINTENANCE THERAPY; MENTAL DISEASE; NONCARDIAC CHEST PAIN; PAIN; PAIN THRESHOLD; PANIC; PREVALENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH FUNDOPLICATION; TREATMENT DURATION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

CHEST PAIN; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL MOTILITY DISORDERS; ESOPHAGEAL SPHINCTER, LOWER; HUMANS; INCIDENCE; UNITED STATES;

EID: 42449113443     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3181684c6b     Document Type: Conference Paper

References (102)

1. Jerlock M, Welin C, Rosengren A, et al. Pain characteristics in patients with unexplained chest pain and patients with ischemic heart disease. Eur J Cardiovasc Nurs. 2007;6:130-136.
2. Ockene IS, Shay MJ, Alpert JS, et al. Unexplained chest pain in patients with normal arteriograms. N Engl J Med. 1980;303:1249-1252.
3. Dumville JC, MacPherson H, Griffht K, et al. Non-cardiac chest pain: a retrospective cohort study of patients who attended a Rapid Access Chest Pain Clinic. Fam Pract. 2007;24:152-157.
4. Sekhri N, Feder GS, Junghans C, et al. How effective are rapid access chest pain clinics? Prognosis of incident angina and noncardiac chest pain in 8762 consecutive patients. Heart. 2007;93:458-463.
5. Robertson N, Javed N, Samani N, et al. Psychological morbidity and illness appraisals of patients with cardiac and non-cardiac chest pain attending a Rapid Access Chest Pain Clinic: a longitudinal cohort study. Heart. [Epub ahead of print May 31, 2007].
6. Rome III: The Functional Gastrointestinal Disorders. 3rd ed. McLean, VA: Degnon Associates, Inc; 2006.
7. Mudipalli RS, Remes-Troche JM, Andersen L, et al. Functional chest pain-esophageal or overlapping functional disorder. J Clin Gastroenterol. 2007;41:264-269.
8. Chiocca JC, Olmos JA, Salis GB, et al. Prevalence, clinical spectrum and atypical symptoms of gastro-oesophageal reflux in Argentina: a nationwide population-based study. Aliment Pharmacol Ther. 2005;22:331-342.
9. Wong WM, Lai KC, Lam KF, et al. Prevalence, clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population: a population-based study. Aliment Pharmacol Ther. 2003;18:595-604.
10. Locke III GR, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
11. Mousavi S, Tosi J, Eskandarian R, et al. Role of clinical presentation in diagnosing reflux-related non-cardiac chest pain. J Gastroenterol Hepatol. 2007;22:218-221.
12. Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting - a population-based study. Aliment Pharmacol Ther. 2003;17:1115-1124.
13. Tew R, Guthrie EA, Creed FH, et al. A long-term follow-up study of patients with ischemic heart disease versus patients with nonspecific chest pain. J Psychosom Res. 1995;39:977-985.
14. Wong WM, Risner-Adler S, Beeler J, et al. Noncardiac chest pain: the role of the cardiologist - a national survey. J Clin Gastroenterol. 2005;39:858-862.
15. Wong WM, Beeler J, Risner-Adler S, et al. Attitudes and referral patterns of primary care physicians when evaluating subjects with noncardiac chest pain - a national survey. Dig Dis Sci. 2005;50:656-661.
16. Eslick GD, Talley NJ. Non-cardiac chest pain: predictors of health care seeking, the types of health care professional consulted, work absenteeism and interruption of daily activities. Aliment Pharmacol Ther. 2004;20:909-915.
17. Potts SG, Bass CM. Psychological morbidity in patients with chest pain and normal or near-normal coronary arteries: a long-term follow-up study. Psychol Med. 1995;254:339-347.
18. Eslick GD. Noncardiac chest pain: epidemiology, natural history, health care seeking, and quality of life. Gastroenterol Clin North Am. 2004;33:1-23.
19. Fass R, Naliboff B, Higa L, et al. Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology. 1998;115:1363-1373.
20. Beedassy A, Katz PO, Gruber A, et al. Prior sensitization of esophageal mucosa by acid reflux predisposes to reflux-induced chest pain. J Clin Gastroenterol. 2000;31:121-124.
21. Dekel R, Martinez-Hawthorne SD, Guillen RJ, et al. Evaluation of symptom index in identifying gastroesophageal reflux disease-related noncardiac chest pain. J Clin Gastroenterol. 2004;38:24-29.
22. Dickman R, Mattek N, Holub J, et al. Prevalence of upper gastrointestinal tract findings in patients with noncardiac chest pain versus those with gastroesophageal reflux disease (GERD)-related symptoms: results from a national endoscopic database. Am J Gastroenterol. 2007;102:1173-1179.
23. Dekel R, Pearson T, Wendel C, et al. Assessment of oesophageal motor function in patients with dysphagia or chest pain-the clinical outcomes research initiative experience. Aliment Pharmacol Ther. 2003;18:1083-1089.
24. Katz PO, Dalton CB, Richter JE, et al. Esophageal testing of patients with noncardiac chest pain or dysphagia. Results of three years' experience with 1161 patients. Ann Intern Med. 1987;106:593-597.
25. Rencoret G, Csendes A, Henriquez A. Esophageal manometry in patients with non cardiac chest pain. Rev Méd Chile. 2006;134:291-298.
26. Achem SR, Kolts BE, Wears R, et al. Chest pain associated with nutcracker esophagus: a preliminary study of the role of gastroesophageal reflux. Am J Gastroenterol. 1993;88:187-192.
27. Barish CF, Castell DO, Richter JE. Graded esophageal balloon distention. A new provocative test for noncardiac chest pain. Dig Dis Sci. 1986;31:1292-1298.
28. Tougas G. The autonomic nervous system in functional bowel disorders. Gut. 2000;47:iv78-iv80.
29. Sarkar S, Aziz Q, Woolf CJ, et al. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet. 2000;356:1154-1159.
30. Fass R, Fennerty MB, Johnson C, et al. Correlation of ambulatory 24-hour esophageal pH monitoring results with symptom improvement in patients with noncardiac chest pain due to gastroesophageal reflux disease. J Clin Gastroenterol. 1999;28:36-39.
31. Borjesson M, Pilhall M, Eliasson T, et al. Esophageal visceral pain sensitivity: effects of TENS and correlation with manometric findings. Dig Dis Sci. 1998;43:1621-1628.
32. Mujica VR, Mudipalli RS, Rao SS. Pathophysiology of chest pain in patients with nutcracker esophagus. Am J Gastroenterol. 2001;96:1371-1377.
33. Hollerbach S, Bulat R, May A, et al. Abnormal cerebral processing of oesophageal stimuli in patients with noncardiac chest pain (NCCP). Neurogastroenterol Motil. 2000;12:555-565.
34. Sarkar S, Thompson DG, Woolf CJ, et al. Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression. Am J Gastroenterol. 2004;99:1998-2006.
35. Aziz Q. Acid sensors in the gut: a taste of things to come. Eur J Gastroenterol Hepatol. 2001;13:885-888.
36. Fagring AJ, Gaston-Johannson F, Kjellgren KI, et al. Unexplained chest pain in relation to psychosocial factors and health-related quality of life in men and women. Eur J Cardiovasc Nurs. 2007;6:329-336.
37. Cheng C, Wong WM, Lai KC, et al. Psychosocial factors in patients with noncardiac chest pain. Psychosom Med. 2003;65:443-449.
38. Fass R, Malagon I, Schmulson M. Chest pain of esophageal origin. Curr Opin Gastroenterol. 2001;17:376-380.
39. Steele R, McNaughton T, McConahy M, et al. Chest pain in emergency department patients: If the pain is relieved by nitroglycerin, it is more likely to be cardiac chest pain? Can J Emerg Med. 2006;8:164-169.
40. Kim JH, P-L R, Park E-H, et al. Clinical usefulness of subgrouping of patients with non-cardiac chest pain according to characteristic symptoms in Korea. Gastroenterology. 2007;22:320-325.
41. Faybush EA, Fass R. Diagnosis of Noncardiac Chest Pain. In: Fass R, Eslick GD, eds. Noncardiac Chest Pain - A Growing Medical Problem. San Diego: Plural Publishing; 2007: 83-101.
42. Prakash C, Clouse RE. Value of extended recording time with wireless pH monitoring in evaluating gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2005;3:329-334.
43. Prakash C, Clouse RE. Wireless pH monitoring in patients with non-cardiac chest pain. Am J Gastroenterol. 2006;101:446-452.
44. Xia HH, Lai KC, Lam SK. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2003;17:369-377.
45. Young MF, Sanowski RA, Talbert GA, et al. Omeprazole administration as a test for gastroesophageal reflux (abstract). Gastroenterology. 1992;102:192.
46. Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol. 2002;35:307-314.
47. Bautista J, Fullerton H, Briseno M, et al. The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain - a randomized, double-blind, placebo-controlled, crossover trial. Aliment Pharmacol Ther. 2004;19:1123-1130.
48. Cremonini F, Wise J, Moayyedi P, et al. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta-analysis. Am J Gastroenterol. 2005;100:1226-1232.
49. Wang WH, Huang JQ, Zheng GF, et al. Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? A meta-analysis. Arch Intern Med. 2005;165:1222-1228.
50. Fass R, Bautista J, Janarthanan S. Treatment of gastroesophageal reflux disease. Clin Cornerstone. 2003;5:18-29.
51. Kitchin L, Castell D. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med. 1991;151:448-454.
52. Fang J, Bjorkman D. A critical approach to noncardiac chest pain: pathophysiology, diagnosis, and treatment. Am J Gastroenterol. 2001;96:958-968.
53. DeMeester T, O'Sullivan G, Bermudez G, et al. Esophageal function in patients with angina-type chest pain and normal coronary angiograms. Ann Surg. 1982;196:488-498.
54. Achem S, Kolts B, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci. 1997;42:2138-2145.
55. Louis E, Jorissen L, Bastens B, et al. Atypical symptoms of GORD in Belgium: epidemiological features, current management and open label treatment with 40mg esomeprazole for one month. Acta Gastroenterol Belg. 2006;Apr-June:203-208.
56. Dore MP, Pedroni A, Pes GM, et al. Effect of antisecretory therapy on atypical symptoms in gastroesophageal reflux disease. Dig Dis Sci. 2007;52:463-468.
57. Liuzzo JP, Ambrose JA, Diggs P. Proton-pump inhibitor use by coronary artery disease patients is associated with fewer chest pain episodes, emergency department visits and hospitalizations. Aliment Pharmacol Ther. 2005;22:95-100.
58. Borzecki A, Pedrosa M, Prashker M. Should noncardiac chest pain be treated empirically? A cost-effectiveness analysis. Arch Intern Med. 2000;160:844-852.
59. Patti M, Molena D, Fisichella P, et al. Gastroesophageal reflux disease (GERD) and chest pain. Results of laparoscopic antireflux surgery. Surg Endosc. 2002;16:563-566.
60. Farrell T, Richardson W, Trus T, et al. Response of atypical symptoms of gastro-oesophageal reflux to antireflux surgery. Br J Surg. 2001;88:1649-1652.
61. So J, Zeitels S, Rattner D. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998;124:28-32.
62. Cheung TK, Lim PWY, Wong BC. Noncardiac chest pain - an Asia-Pacific survey on the views of primary care physicians. Dig Dis Sci. 2007;52:3043-3048.
63. Cheung TK, Lim PWY, Wong BCY. The view of gastroenterologists on non-cardiac chest pain in Asia. Aliment Pharmacol Ther. 2007;26:597-603.
64. Orlando R, Bozymski E. Clinical and manometric effects of nitroglycerin in diffuse esophageal spasm. N Engl J Med. 1989;289:23-25.
65. Millaire A, Ducloux G, Marquand A, et al. Clinical effects and effects on esophageal motility. Arch Mal Coeur Vaiss. 1989;82:63-68.
66. Swamy N. Esophageal spasm: clinical and manometric response to nitroglycerine and long acting nitrites. Gastroenterology. 1977;72:23-27.
67. Kikendall J, Mellow M. Effect of sublingual nitroglycerin and long-acting nitrate preparations on esophageal motility. Gastroenterology. 1980;79:703-706.
68. Mellow M. Effect of isosorbide and hydralazine in painful primary esophageal motility disorders. Gastroenterology. 1982;83:364-370.
69. Richter J, Dalton C, Buice R, et al. Nifedipine: a potent inhibitor of contractions in the body of the human esophagus. Studies in healthy volunteers and patients with the nutcracker esophagus. Gastroenterology. 1985;89:549-554.
70. Davies H, Lewis M, Rhodes J, et al. Trial of nifedipine for prevention of oesophageal spasm. Digestion. 1987;36:81-83.
71. Nasrallah S, Tommaso C, Singleton R, et al. Primary esophageal motor disorders: clinical response to nifedipine. South Med J. 1985;78:312-315.
72. Konrad-Danlhoff I, Baunack A, Ramsch K, et al. Effect of the calcium antagonists nifedipine, nirendipine, nimodipine, and nisoldipine on esophageal motility in man. Eur J Pharmacol. 1991;41:313-316.
73. Richter J, Spurling T, Cordova C, et al. Effects of oral calcium blocker, diltiazem, on esophageal contractions. Studies in volunteers and patients with nutcracker esophagus. Dig Dis Sci. 1984;29:649-656.
74. Cattau E Jr, Castell D, Johnson D, et al. Diltiazem therapy for symptoms associated with nutcracker esophagus. Am J Gastroenterol. 1991;86:272-276.
75. Drenth J, Bos L, Engels L. Efficacy of diltiazem in the treatment of diffuse oesophageal spasm. Aliment Pharmacol Ther. 1990;4:411-416.
76. Lee LI, Park H, Kim TH, et al. The effect of sildenafil on esophageal motor function in healthy subjects and patients with nutcracker esophagus. Neurogastroenterol Motil. 2003;15:617-623.
77. Bortolotti M, Pandolfo N, Giovannini M, et al. Effect of sildenafil on hypertensive lower esophageal sphincter. Eur J Clin Invest. 2002;32:682-685.
78. Bassoti G, Gaburri M, Imbimbo B, et al. Manometric evaluation of cimetropium bromide activity in patients with the nutcracker oesophagus. Scand J Gastroenterol. 1988;23:1079-1084.
79. Egbunike I, Chaffee B. Antidepressants in the management of chronic pain syndromes. Pharmacotherapy. 1990;10:262-270.
80. Becker B, Morel N, Vanbellinghen A, et al. Blockade of calcium entry in smooth muscle cells by the antidepressant imipramine. Biochem Pharmacol. 2004;68:833-842.
81. Peghini P, Katz P, Castell D. Imipramine decreases oesophageal pain perception in human male volunteers. Gut. 1998;42:807-813.
82. Cannon 3rd RO, Quyyumi AA, Mincemoyer R, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med. 1994;330:1411-1417.
83. Gorelick A, Koshy S, Hooper F, et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol. 1998;275:G460-G466.
84. Clouse RE, Lustman PJ, Eckert TC, et al. Low-dose trazodone for symptomatic patients with esophageal contraction abnormalities. A double-blind, placebo-controlled trial. Gastroenterology. 1987;92:1027-1036.
85. Handa M, MIne K, Yamamoto H, et al. Antidepressant treatment of patients with diffuse esophageal spasm: a psychosomatic approach. J Clin Gastroenterol. 1999;28:228-232.
86. Varia I, Logue E, O'Connor C, et al. Randomized trial of sertaline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000;140:367-372.
87. Broekaert D, Fischler B, Sifrim D, et al. Influence of citalopram, a selective serotonin, reuptake inhibitor, on oesophageal hypersensitivity: a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2006;23:365-370.
88. Bradette M, Delvaux M, Staumont G, et al. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci. 1994;39:1171-1178.
89. Schwetz I, Naliboff B, Munakata J, et al. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2004;19:123-131.
90. Johnston B, Shils J, Leite L, et al. Effects of octreotide on esophageal visceral perception and cerebral evoked potentials induced by balloon distension. Am J Gastroenterol. 1994;94:65-70.
91. Crea F, Pupita G, Galassi A, et al. Role of adenosine in pathogenesis of anginal pain. Circulation. 1990;81:164-172.
92. Rao SS, Mudipalli RS, Mujica VR, et al. An open-label trial of theophylline for functional chest pain. Dig Dis Sci. 2002;47:2763-2768.
93. Rao SS, Mudipalli RS, Remes-Troche JM, et al. Theophylline improves esophageal chest pain-a randomized, placebo-controlled study. Am J Gastroenterol. 2007;102:930-938.
94. Beitman B, Basha I, Trombka L, et al. Pharmacotherapeutic treatment of panic disorder in patients presenting with chest pain. J Fam Pract. 1989;28:177-180.
95. Wulsin L, Maddock R, Beitman B, et al. Clonazepam treatment of panic disorder in patients with recurrent chest pain and normal coronary arteries. Int J Psychiatry Med. 1999;29:97-105.
96. Tack J, Sarnelli G. Serotonergic modulation of visceral sensation: upper gastrointestinal tract. Gut. 2002;51:i77-i80.
97. Rodriguez-Stanley S, Zubaidi S, Proskin H, et al. Effect of tegaserod on esophageal pain threshold, regurgitation, and symptom relief in patients with functional heartburn and mechanical sensitivity. Clin Gastroenterol Hepatol. 2006;4:442-450.
98. Miller L, Pullela S, Parkman H, et al. Treatment of chest pain in patients with noncardiac, nonreflux, nonachalasia spastic esophageal motor disorders using botulinum toxin injection into the gastroesophageal junction. Am J Gastroenterol. 2002;97:1640-1646.
99. Liu JL, Carr-Locke DL, Osterman MT, et al. Endoscopic treatment for atypical manifestations of gastroesophageal reflux disease. Am J Gastroenterol. 2006;101:440-445.
100. van Peski-Oosterbaan A, Spinhoven P, van Rood Y, et al. Cognitive-behavioral therapy for noncardiac chest pain: a randomized trial. Am J Med. 1999;106:424-429.
101. Ryan M, Gervirtz R. Biofeedback-based psychophysiological treatment in a primary care setting: an initial feasibility study. Appl Psychophysiol Biofeedback. 2004;29:79-93.
102. Jones H, Cooper P, Miller V, et al. Treatment of non cardiac chest pain: a controlled trial of hypnotherapy. Gut. 2006;55:1403-1408.